Date
11/30/14
Alumnus, Peter Senter is a recipient of this year's LAS Alumni Achievement Award for his breakthough research in the use of antibodies to target cancer cells without destroying nearby healthy cells. He is one of the founding members of Seattle Genetics, which developed the drug Adcetris, an important treatment for Hodgkin’s lymphoma, the most common cancer among teenagers between the ages of 15 and 19.
Dr. Senter received his PhD with Professor Robert Coates, in 1981. The research of Professor John Katzenellenbogen has been influential in Sentris' use of antibodies attached to anti-cancer drugs for targeted cancer therapies.
Peter Senter LAS Alumni Profile